KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Intangibles (2017 - 2025)

Historic Intangibles for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $587.9 million.

  • Amneal Pharmaceuticals' Intangibles fell 2464.16% to $587.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $587.9 million, marking a year-over-year decrease of 2464.16%. This contributed to the annual value of $732.4 million for FY2024, which is 1774.95% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Intangibles is $587.9 million, which was down 2464.16% from $649.5 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Intangibles registered a high of $1.3 billion during Q2 2021, and its lowest value of $587.9 million during Q3 2025.
  • In the last 5 years, Amneal Pharmaceuticals' Intangibles had a median value of $1.0 billion in 2023 and averaged $983.5 million.
  • Its Intangibles has fluctuated over the past 5 years, first plummeted by 2625.73% in 2021, then tumbled by 420.73% in 2022.
  • Amneal Pharmaceuticals' Intangibles (Quarter) stood at $1.2 billion in 2021, then decreased by 6.07% to $1.1 billion in 2022, then dropped by 18.76% to $890.4 million in 2023, then decreased by 17.75% to $732.4 million in 2024, then decreased by 19.72% to $587.9 million in 2025.
  • Its last three reported values are $587.9 million in Q3 2025, $649.5 million for Q2 2025, and $689.1 million during Q1 2025.